FasL cross-linking inhibits activation of human peripheral T cells

International Immunology

Volumn 21, Issue 5, 2009, Pages 587-598

  Paulsen, Maren ^a   Mathew, Biny ^a   Qian, Jing ^a   Lettau, Marcus ^a   Kabelitz, Dieter ^a   Janssen, Ottmar ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

CD95L; Cell activation; Co stimulation; FasFc; Signal transduction

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; FAS ANTIGEN; FAS LIGAND; T LYMPHOCYTE RECEPTOR;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN FUNCTION; PROTEIN IMMOBILIZATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD28; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; FAS LIGAND PROTEIN; HUMANS; LYMPHOCYTE ACTIVATION; PHOSPHORYLATION; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 65549122152     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxp028     Document Type: Article

References (42)

1. Ju, S. T., Panka, D. J., Cui, H. et al. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444.
2. Dhein, J., Walczak, H., Baumler, C., Debatin, K. M. and Krammer, P. H. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438.
3. Brunner, T., Mogil, R. J., LaFace, D. et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441.
4. Gruss, H. J. and Dower, S. K. 1995. Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood 85:3378.
5. Stuber, E., Neurath, M., Calderhead, D., Fell, H. P. and Strober, W. 1995. Crosslinking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2:507.
6. Wiley, S. R., Goodwin, R. G. and Smith, C. A. 1996. Reverse signaling via CD30 ligand. J. Immunol. 157:3635.
7. Suzuki, I. and Fink, P. J. 1998. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J. Exp. Med. 187:123.
8. Sun, M. and Fink, P. J. 2007. A new class of reverse signaling costimulators belongs to the TNF family. J. Immunol. 179:4307.
9. Watts, A. D., Hunt, N. H., Wanigasekara, Y. et al. 1999. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. EMBO J. 18:2119.
10. Sun, M., Lee, S., Karray, S., Levi-Strauss, M., Ames, K. T. and Fink, P. J. 2007. Cutting edge: Two distinct motifs within the Fas ligand tail regulate Fas ligand-mediated costimulation. J. Immunol. 179: 5639.
11. Sun, M., Ames, K. T., Suzuki, I. and Fink, P. J. 2006. The cytoplasmic domain of Fas ligand costimulates TCR signals. J. Immunol. 177:1481.
12. Desbarats, J., Duke, R. C. and Newell, M. K. 1998. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat. Med. 4:1377.
13. Linkermann, A., Qian, J., Kabelitz, D. and Janssen, O. 2003. The Fas Ligand as a death factor and signal transducer? Signal Transduction 3:33.
14. Linkermann, A., Qian, J., Lettau, M., Kabelitz, D. and Janssen, O. 2005. Considering Fas ligand as a target for therapy. Expert Opin. Ther. Targets 9:119.
15. Hane, M., Lowin, B., Peitsch, M., Becker, K. and Tschopp, J. 1995. Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain. FEBS Lett. 373:265.
16. Wenzel, J., Sanzenbacher, R., Ghadimi, M. et al. 2001. Multiple interactions of the cytosolic polyproline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factor. FEBS Lett. 509:255.
17. Ghadimi, M. P., Sanzenbacher, R., Thiede, B. et al. 2002. Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178). FEBS Lett. 519:50.
18. Suzuki, I. and Fink, P. J. 2000. The dual function of Fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proc. Natl Acad. Sci. USA 97:1707.
19. Suzuki, I., Martin, S., Boursalian, T. E., Beers, C. and Fink, P. J. 2000. Fas ligand costimulates the in vivo proliferation of CD8+ T cells. J. Immunol. 165:5537.
20. Lettau, M., Qian, J., Kabelitz, D. and Janssen, O. 2004. Activation-dependent FasL expression in T lymphocytes and natural killer cells. Signal Transduction 4:206.
21. Blott, E. J. and Griffiths, G. M. 2002. Secretory lysosomes. Nat. Rev. Mol. Cell Biol. 3:122.
22. Bossi, G., Trambas, C., Booth, S., Clark, R., Stinchcombe, J. and Griffiths, G. M. 2002. The secretory synapse: The secrets of a serial killer. Immunol. Rev. 189:152.
23. Griffiths, G. M. 2003. Endocytosing the death sentence. J. Cell Biol. 160:155.
24. Trambas, C. M. and Griffiths, G. M. 2003. Delivering the kiss of death. Nat. Immunol. 4:399.
25. Lettau, M., Qian, J., Linkermann, A. et al. 2006. The adaptor protein Nck interacts with Fas ligand: Guiding the death factor to the cytotoxic immunological synapse. Proc. Natl Acad. Sci. USA 103:5911.
26. Lettau, M., Schmidt, H., Kabelitz, D. and Janssen, O. 2006. Secretory lysosomes and their cargo in T and NK cells. Immunol. Lett. 108:10.
27. Boursalian, T. E. and Fink, P. J. 2003. Mutation in fas ligand impairs maturation of thymocytes bearing moderate affinity T cell receptors. J. Exp. Med. 198:349.
28. Cohen, P. L. and Eisenberg, R. A. 1991. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:243.
29. Takahashi, T., Tanaka, M., Brannan, C. I. et al. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969.
30. Adam-Klages, S., Adam, D., Janssen, O. and Kabelitz, D. 2005. Death receptors and caspases: Role in lymphocyte proliferation, cell death, and autoimmunity. Immunol. Res. 33:149.
31. Nakano, K., Saito, K., Mine, S., Matsushita, S. and Tanaka, Y. 2007. Engagement of CD44 up-regulates Fas ligand expression on T cells leading to activation-induced cell death. Apoptosis 12:45.
32. Walunas, T. L., Lenschow, D. J., Bakker, C. Y. et al. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
33. Wells, A. D., Walsh, M. C., Bluestone, J. A. and Turka, L. A. 2001. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J. Clin. Invest. 108:895.
34. Alderson, M. R., Tough, T. W., Davis-Smith, T. et al. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181:71.
35. Maksimow, M., Soderstrom, T. S., Jalkanen, S., Eriksson, J. E. and Hanninen, A. 2006. Fas costimulation of naive CD4 T cells is controlled by NF-kappaB signaling and caspase activity. J. Leukoc. Biol. 79:369.
36. Strauss, G., Osen, W., Knape, I., Jacobsen, E. M., Muller, S. M. and Debatin, K. M. 2007. Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity. Cell Death Differ. 14:480.
37. Mempel, T. R., Henrickson, S. E. and Von Andrian, U. H. 2004. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427:154.
38. Guo, Z., Zhang, M., An, H. et al. 2003. Fas ligation induces IL-1beta-dependent maturation and IL-1beta-independent survival of dendritic cells: Different roles of ERK and NF-kappaB signaling pathways. Blood 102:4441.
39. Ashany, D., Savir, A., Bhardwaj, N. and Elkon, K. B. 1999. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. J. Immunol. 163:5303.
40. Lundqvist, A., Nagata, T., Kiessling, R. and Pisa, P. 2002. Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L). Cancer Immunol. Immunother. 51:139.
41. Brunner, T., Yoo, N. J., Griffith, T. S., Ferguson, T. A. and Green, D. R. 1996. Regulation of CD95 ligand expression: A key element in immune regulation? Behring Inst. Mitt. 97:161.
42. French, L. E., Wilson, A., Hahne, M., Viard, I., Tschopp, J. and MacDonald, H. R. 1997. Fas ligand expression is restricted to nonlymphoid thymic components in situ. J. Immunol. 159:2196.